(Warkus and Marikawa, 2018) demonstrated that neither fluoxetine nor its main metabolite norfluoxetine (norfluoxin) had an effect on cardiomyocytes in the P19C5 embryoid body (EB) model in mice
Over time, this can make daily life harder
Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma around obesity treatment drive troves of patients some studies estimate roughly half or more to stop GLP-1s within a year and risk regaining the weight they lost
Navigating Emotional Shifts on GLP-1 Drugs GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are primarily designed to support blood-sugar control and weight loss
Heart disease is the leading cause of death in women, and nearly 80% of women ages 40 to 60 have one or more risk factors for coronary heart disease
What Users Actually Experience (Not Just Theory) Instead of clinical terms, heres how most people describe GLP-1 side effects: I feel full even after a few bites I get slightly nauseous after eating My digestion feels slow or heavy I dont feel hungry, but I also feel low energy These effects are directly linked to how GLP-1 drugs influence appetite and digestion
